secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001625101-22-000065
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences reports Q3 net loss $18M, tightens focus on cardiac ablation, secures $65M loan from chairman
--------------------------------------------------------------------------------

- Q3 GAAP net loss $18.0M vs $14.3M in prior year; no revenue recorded.
- Strategic pivot to cardiac cellular ablation for atrial fibrillation; dermatology business inventory reserve of $7.2M.
- Entered $65M term loan at 5% interest, due March 2024, from Executive Chairman Robert Duggan.
- Appointed Kevin Danahy as CEO, Darrin Uecker as CTO, and Robert Duggan as Executive Chairman.
- Anticipates quarterly cash burn ~$8M from Q1 2023; cash $69.2M at Sep 30 vs $28.6M at Dec 31, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000162510122000065/0001625101-22-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000162510122000065/plse-20221110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001625101-22-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer